<DOC>
	<DOC>NCT01558089</DOC>
	<brief_summary>This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece</brief_summary>
	<brief_title>Good EULAR Response In Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description>All subjects enrolled should meet the usual prescribing criteria for Etanercept as per the local product information and should be entered into the study at the investigator's discretion</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1. signed and dated informed consent document 2. 18 years of age and older at the time of consent 3. Patients with moderatetosevere active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria 4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC, 5. Patients with DAS28 ≥ 3.2 6. Duration of disease symptoms ≥ 6 weeks and ≤2 years 7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice. 1. Contraindications according to the SmPC 2. History of or present antiTNFa or other biologic therapy for the treatment of RA 3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>